These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24048905)

  • 1. New therapeutical horizons in the management of postmenopausal osteoporosis.
    Migliaccio S; Fornari R; Greco EA; Di Luigi L; Lenzi A
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S117-9. PubMed ID: 24048905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic targets for osteoporosis: beyond denosumab.
    Lim V; Clarke BL
    Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies.
    Iolascon G; Resmini G; Tarantino U
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S19-22. PubMed ID: 24046050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis.
    Chavassieux P; Asser Karsdal M; Segovia-Silvestre T; Neutzsky-Wulff AV; Chapurlat R; Boivin G; Delmas PD
    J Bone Miner Res; 2008 Jul; 23(7):1076-83. PubMed ID: 18302508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New bone density conservation agents for osteoporosis under research and development: Anti-RANKL antibody].
    Wada S; Fukawa T; Kamiya S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():459-62. PubMed ID: 18161149
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
    Mukherjee K; Chattopadhyay N
    Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis: now and the future.
    Rachner TD; Khosla S; Hofbauer LC
    Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
    Schultz TC; Valenzano JP; Verzella JL; Umland EM
    Womens Health (Lond); 2015 Nov; 11(6):805-14. PubMed ID: 26344800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
    Riggs BL; Parfitt AM
    J Bone Miner Res; 2005 Feb; 20(2):177-84. PubMed ID: 15647810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bone histomorphometry;A role of evaluation for bone quality and mechanical strength].
    Yamamoto N; Takahashi H; Shimakura T
    Clin Calcium; 2016 Jan; 26(1):9-15. PubMed ID: 26728526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.
    Ma YL; Zeng Q; Donley DW; Ste-Marie LG; Gallagher JC; Dalsky GP; Marcus R; Eriksen EF
    J Bone Miner Res; 2006 Jun; 21(6):855-64. PubMed ID: 16753016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New developments in the treatment of osteoporosis.
    Eriksen EF; Halse J; Moen MH
    Acta Obstet Gynecol Scand; 2013 Jun; 92(6):620-36. PubMed ID: 22646526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2014 Sep; 56(1452):91-6. PubMed ID: 25247344
    [No Abstract]   [Full Text] [Related]  

  • 19. [Mechanisms of action of anticatabolic drugs used in osteoporosis therapy].
    Kryśkiewicz E; Lorenc RS
    Endokrynol Pol; 2009; 60(2):134-44. PubMed ID: 19396757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.